BZT also decreases adhesion of myeloma plasma cells to stromal cells and disrupts secretion of specific cytokines in the bone marrow microenvironment such as vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) [4]. Here, TNF is linked to plasma cell myeloma.